Curaleaf And Aurora Are Now Sniping At Each Other

Curaleaf And Aurora Are Now Sniping At Each Other

Tue, August 25, 2026 at 9:34 PM GMT+3 2 min read

• ACB -0.25%
• NVDA -1.59%

BREAKING NEWS

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Curaleaf's hostile, $4 per share bid for Aurora Cannabis devolved into back-and-forth sniping. On Monday, the two companies traded press-released barbs amplified by both CEOs.

Let's go to the tape. Aurora cautioned shareholders that Curaleaf's hostile takeover bid "appears to contain inaccurate statements about Aurora's business" and again told them to take no action while its special committee reviews the offer.

At the heart of the proposed takeover is Aurora's EU-GMP certified cannabis cultivation facilities. The European cannabis market, led by Germany, is growing much faster than the U.S. or Canadian markets, and import restrictions are tightening, meaning that certification is key for growth.

Curaleaf wants those assets on the cheap. The offer is essentially a "bear hug," made famous in Season 1 of Succession. Curaleaf's offering a premium on Aurora's average share price, so in its view, it's an offer Aurora's shareholders can't refuse. But Aurora's telling shareholders that it's a good steward of the business and that they shouldn't give in to Curaleaf.

"Curaleaf's timing and public comments appear to be a transparent attempt to pressure Aurora shareholders into making a short-term decision for the benefit of Curaleaf shareholders," Aurora CEO Miguel Martin said in the statement.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Aurora disputed Curaleaf's take on its German business, saying the flagged reimbursement segment made up less than 10% of German volume before regulatory changes hit, and called Curaleaf's cultivation claims "inaccurate and outdated." It also cited its August 19 U.K. acquisitions and its top market share in Poland.

Over the last year, Aurora's shares fell about 23%, inclusive of the bump after Curaleaf first went public with the bid. Over the same time period Curaleaf's OTC-listed shares are up about 8%.

The reply?

"Aurora's hollow protests and completely misleading statistics change nothing about reality," Curaleaf CEO Boris Jordan said.